Firouz Mohsenian
About Firouz Mohsenian
Firouz Mohsenian is a Research Manager specializing in Cell Biology at Capricor Therapeutics, Inc., where he leads the development of assays for CAP-1002. He has a background in research and development across several biotechnology companies, with significant contributions to cancer therapy and cell engineering.
Work at Capricor Therapeutics
Currently, Firouz Mohsenian serves as the Research Manager for Cell Biology at Capricor Therapeutics, Inc. since 2022. In this role, he has led the development of CAP-1002 Identity and Potency Assays, utilizing gene expression analysis and RNA sequencing. He has collaborated with Quality Assurance to ensure compliance with documentation standards for assay development. Mohsenian has also authored extensive standard operating procedures and reports for CAP-1002 assays, and has trained team members on these procedures. His contributions are integral to the advancement of CAP-1002, which is undergoing a Phase 3 clinical trial for Duchenne Muscular Dystrophy.
Previous Experience in Biotechnology
Firouz Mohsenian has a diverse background in biotechnology, having worked in various capacities prior to his current role. He was a Senior Scientist at Capricor Therapeutics, Inc. for 11 months in 2021-2022. Before that, he served as a Research Scientist at BPS Bioscience Inc. for one year in 2020-2021. His earlier experience includes a position as a Scientist in Research and Development at GenMark Diagnostics for one year in 2010-2011, and as a Scientist in the Cell Engineering Unit at Intrexon Corporation for eight years from 2011 to 2019.
Education and Expertise
Firouz Mohsenian studied at San Diego State University, where he gained foundational knowledge in cell biology and related fields. His expertise encompasses gene expression analysis, RNA sequencing, and the development of potency assays. Mohsenian has demonstrated proficiency in authoring standard operating procedures and conducting research that contributes to advancements in cell therapy and cancer treatment.
Research Contributions and Publications
Mohsenian has made significant contributions to scientific research, particularly in the field of exosomes and cancer therapy. He presented a poster at the American Association of Extracellular Vesicles (AAEV) 2023 conference, focusing on exosomes loaded with siRNA targeting the RRM2 gene for ovarian cancer therapy. He co-authored publications on methods for loading nucleic acid cargos in 293F exosomes and on the use of exosomes loaded with siRNA to induce apoptosis in the SKOV3 ovarian cancer cell line.